Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

  • Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers:
    • Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc)
    • Oncology BU grew 9% (cc) driven by AAA[2] (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc)
  • Full year core[1] operating income grew 8% mainly driven by higher sales and gross margin expansion
  • Net income was USD …
/by

Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US

Princeton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.

SYMJEPI will be rolled out through a phased launch, first in the institutional setting – an established channel where Sandoz Inc. has significant experience and knowledge – followed by introduction into …

/by

Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries

  • Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
  • Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
  • Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging

Holzkirchen, January 16, 2019 – Sandoz, a Novartis division, …

/by

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

  • reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder
  • Cleared by the FDA in December, reSET-O is available immediately
  • As part of a broader focus on digital healthcare solutions at Novartis, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

HOLZKIRCHEN, January 7, 2018 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD …

/by

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

  • Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart
  • Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030[1],[2]
  • Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation

…

/by

Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

  • Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics
  • Program will combine established microbiology laboratory techniques with advanced bioinformatics and AI methods
  • Short-term focus on repurposing existing antibiotics to treat infections involving multi-drug-resistant pathogens

Holzkirchen, December 18, 2018 – Sandoz today announces the signature of a strategic collaboration agreement with Ares Genetics GmbH, to …

/by

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

  • reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
  • Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas
  • Sandoz will lead U.S. commercial launch, anticipated in coming days in Q4
  • As part of broader Novartis digital revolution, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

…

/by

Sandoz certified Top Employer Asia Pacific 2019

  • Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC)
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to build a great place to work

Holzkirchen, December 4, 2018 – Sandoz, a Novartis division, has been certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region. Sandoz is certified in five Asia …

/by

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

  • Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1]
  • Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile neutropenia, some of the most serious side effects of chemotherapy [2]
  • Sandoz demonstrates commitment to making access happen for patients with eight biosimilars approved in EU, including five in last 18 months

Holzkirchen, November 27, 2018 – Sandoz, a Novartis division …

/by

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

  • reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)
  • Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone
  • Sandoz and Novartis continue to embrace digital technologies to enhance R&D and deliver better outcomes for patients

Holzkirchen, November 19, 2018 – Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch …

/by